Applications are varied and surpass statistical process control with new methodology for process improvements including six sigma for lean manufacturing


the blueprint for process performance and optimisation  

Home | About Us | The Technology | Our Solutions | Applications | Media | Contact Us

 

six-sigma | doe | pat | mspc | case studies  

   
  Over 85 companies are now Curvaceously improving their processes including: AstraZeneca, BAE Systems, BP, DSM,  Dow Corning, Huntsman Petrochemicals, INEOS Chlor, Nestle & Pilkington Glass  
 
Applications of this new process technology are varied and surpass statistical process control with new methodology for process improvements including six sigma


Control Specialists Ltd. form new Alliance Partner offering registered Curvaceous consultancy. Read more here

Visit the website...

 

GPC selected as UK entry for European Business Awards

NEW GPC Explained - Powerpoint Presentation to guide you through GPC

Curvaceous wins IChemE AMEC Award for Innovation & Excellence in an SME

Double Whammy - Curvaceous short listed for IChemE & IEE Innovation Awards

Curvaceous finalists in the Carbon Trust Innovation Awards 2005

Cayuga Partners USA new Curvaceous Agent

Curvaceous solves a Rate Swing problem for Huntsman Petrochemicals.
Read more...

 Winter Newsletter
 


 
     
 

North American Agents

 
 
New York

Stochos Incorporated

 
 
 
New Jersey

Cayuga Partners

 

 

 
  Site Map
  Legal Information
  Copyright Curvaceous Software Ltd
  1998-2006
 All Rights Reserved
  

Process Analytical Technology (PAT)

PAT Explained and Solved using GPC


The Process Analytical Technology (PAT) Initiative established by the Food and Drug Administration (FDA) is the preferred method of encouraging innovation in pharmaceutical manufacturing operations in an aim to build-in product quality in pharmaceutical processes worldwide. Compliance here has several benefits including reduced operating costs and reduced inventory of batches held awaiting test results. Reductions in the number of times, perhaps eventually to zero, the very time consuming, and thus costly, procedures for investigating and correcting the causes of defective batches must also be invoked. These savings will, it is hoped, result in lower drug prices for the consumer.

The Food and Drug Administration (FDA) introduced the Process Analytical Technology (PAT) Initiative which can be solved with new process technology such as GPCNotice that we nor the Food and Drug Administration have said safer drugs. Drugs today are safe because of testing and re-testing after every step of the manufacturing process with capable process technology. The penalty of this lays not so much in excessive testing, if there is any, but in not using the test results to correct the process while there is still time to do so.

The PAT Initiative desires to change the mindset of the pharmaceutical industry to replace “test after each manufacturing step to find out what was made” to “test and correct during each manufacturing step to ensure that what is made is only what is wanted”. The drugs delivered to the consumer will be just as safe as they are today but with much less effort and cost for the manufacturer. This is the result the Food and Drug Administration wants to see.

So to answer the question “why isn't this done already?” we divulge that it was not possible, simply because the process technology solution to the technical problem at the root of it all didn't exist. The root technical problem is that manufacturers need to be able to predict what the properties of the product at the end of the manufacturing step will be if they continue to operate in their present manner. They need to be able to perform these predictions from analysing the many other measurements that can be extracted during the manufacturing step and use their predicted values to alter some of the step variables so that the final result prediction can be corrected, if required, before an actual deviation occurs. Think about this. Not only have they got to predict the consequences of how they are operating, which implies some kind of mathematical model, but they also have to do it before the thing they are predicting shows any change. This means an on-line analyser will not be much help. Following this they have to work out which of the many possible process variables to alter and by how much in order to correct the impending deviation.

 
What kind of mathematical model?

First-principles models which formulate and solve the basic equations of chemical kinetics, equations-of state, thermodynamics and mass balances are not generally available for the time-dependent complex chemistry of AI manufacture or the complex material re-arrangement processes that occur in a tablet press. Statistical and Chemo-metric models need considerable mathematical skills to create and maintain and do not reproduce the non-linear effects common in processes. Neural Net models when built with two hidden layers can reproduce non-linear effects but then become very difficult to train without over training and so require constant expert support.

The Food and Drug Administration (FDA) introduced the Process Analytical Technology (PAT) Initiative which can be solved with new process technology such as GPC

Geometric Process Control (GPC) technology based on multidimensional geometry offers a single solution to most of these difficulties and requires no mathematical knowledge to implement or maintain. Its models are the geometric envelopes of multi-dimensional operating points from past process history where the desired result was achieved. The process operating objective is converted to a geometric intention of being an interior point in the envelope. The usable space inside the envelope is easily found from the present operating points and shown to the process operator in an easily understandable visualisation in terms only of the existing process and predicted quality variables (see figure below).
 

The Food and Drug Administration (FDA) introduced the Process Analytical Technology (PAT) Initiative which can be solved with new process technology such as GPC


With this new process technology, violations of the envelope are immediately apparent and Corrective Advice easily and automatically generated from geometry. The envelope model has a dual response to time based events. This allows it to give very early indication with Avoidance Advice for potential deviations.
 

GPC provides the tools to solve the Food and Drug Administration PAT Initative.
 

For more information or to see how we could help you solve PAT in you plant please contact us.